Methoxy-enriched cationic stilbenes as anticancer therapeutics
- PMID: 32171988
- DOI: 10.1016/j.bioorg.2020.103719
Methoxy-enriched cationic stilbenes as anticancer therapeutics
Abstract
Stilbene-based compounds are largely described for their antioxidant activity. But their use as anticancer chemotherapeutics is hampered by poor pharmacokinetic properties and non-selectivity towards cancer and non-cancer potency. To overcome these drawbacks, twin chain cationic lipid conjugated, methoxy-enriched stilbene derivatives were designed, synthesized and evaluated for their anticancer potency. Our findings reveal that HMSC16, a molecule with the highest number of methoxy groups and with C16-twin chain lipid, is the most potent as well as the most selective anticancer agent when compared to the other synthesized derivatives and commercially available stilbene-based drug, tamoxifen, and resveratrol. To justify these results, we have conducted a series of mechanistic experiments where we found that HMSC16 induced ROS generation, apoptosis, and autophagy by affecting the mitochondrial, lysosomal and nuclear pathways. Further cell cycle analysis data reveals that HMSC16 not only induces cell death but is also involved in the arrest of the cell cycle at the sub-G1 phase. Moreover, HMSC16 showed self-aggregation property owing to a possibly favorable hydrophilic-lipophilic balance. The self-aggregation property of HMSC16 allowed it to entrap hydrophobic drugs, withaferin. With entrapped withaferin, HMSC16 showed additive if not synergistic cell killing effect in HeLa cells. From the above results, we concluded that HMSC16 can be used not just as a drug but also as a drug delivery agent.
Keywords: Anticancer drug; Apoptosis; Autophagy; Cationic lipid; Combination treatment; ROS generation; Self-aggregation; Stilbene.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declared that there is no conflict of interest.
Similar articles
-
Synthesis of Novel Imine Stilbene Analogs Exhibiting Potent Anticancer Activity.Anticancer Agents Med Chem. 2017 Nov 24;17(11):1537-1544. doi: 10.2174/1871520617666170327122929. Anticancer Agents Med Chem. 2017. PMID: 28356012
-
Development of new estradiol-cationic lipid hybrids: ten-carbon twin chain cationic lipid is a more suitable partner for estradiol to elicit better anticancer activity.Eur J Med Chem. 2014 Oct 30;86:653-63. doi: 10.1016/j.ejmech.2014.09.030. Epub 2014 Sep 9. Eur J Med Chem. 2014. PMID: 25222876
-
DNA-binding affinity, cytotoxicity, apoptosis, cell cycle inhibition and molecular docking studies of a new stilbene derivative.Nucleosides Nucleotides Nucleic Acids. 2019;38(2):101-118. doi: 10.1080/15257770.2018.1498517. Epub 2019 Mar 31. Nucleosides Nucleotides Nucleic Acids. 2019. PMID: 30931800
-
Anticancer Activity of Stilbene-Based Derivatives.ChemMedChem. 2017 Apr 20;12(8):558-570. doi: 10.1002/cmdc.201700045. Epub 2017 Mar 28. ChemMedChem. 2017. PMID: 28266812 Review.
-
Mechanism of Resveratrol-Induced Programmed Cell Death and New Drug Discovery against Cancer: A Review.Int J Mol Sci. 2022 Nov 8;23(22):13689. doi: 10.3390/ijms232213689. Int J Mol Sci. 2022. PMID: 36430164 Free PMC article. Review.
Cited by
-
Systematic Studies on Anti-Cancer Evaluation of Stilbene and Dibenzo[b,f]oxepine Derivatives.Molecules. 2023 Apr 18;28(8):3558. doi: 10.3390/molecules28083558. Molecules. 2023. PMID: 37110792 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources